Physician profile
Hendrick Pagan-Torres
NPI 1265896732
$47,051.05
in general payments reported to CMS, 2019-2025
15 companies · $36K in 2025
The $36K reported for 2025 was more than what 89% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $40.00 · 2021: $714 · 2022: $278 · 2023: $424 · 2024: $9,211 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $5,904 · Travel and Lodging: $3,443 · Consulting Fee: $3,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,067.50 |
| Food and Beverage | $5,903.57 |
| Travel and Lodging | $3,442.85 |
| Consulting Fee | $3,162.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $42,219.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $1,299.78 | 2019-2025 | |
| Gilead Sciences, INC. | $897.69 | 2019-2025 | Epclusa, Livdelzi |
| Ipsen Biopharmaceuticals, INC | $536.73 | 2024-2025 | Iqirvo, Bylvay |
| Echosens North America, INC. | $413.18 | 2025 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $342.92 | 2021-2024 | |
| Mirum Pharmaceuticals, INC. | $267.27 | 2024-2025 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $261.04 | 2022-2025 | Livtencity, Entyvio |
| Olympus Latin America, INC. | $235.39 | 2021-2024 | Evis Exera III Colonovideoscope |
| Mallinckrodt Hospital Products INC. | $128.17 | 2023 | Terlivaz |
| Akcea Therapeutics, INC. | $125.01 | 2019 | |
| Boston Scientific Corporation | $102.60 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $97.48 | 2021 | |
| Perspectum Diagnostics Ltd | $72.70 | 2025 | |
| Glaxosmithkline, LLC. | $51.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hendrick Pagan-Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.